Malignancy Risks With Biologic Therapies

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Malignancy Risks With Biologic Therapies

The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently…

read more

Nonserious Infections

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Nonserious Infections

Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the…

read more

Safety of Bisphosphonates

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Safety of Bisphosphonates

Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral…

read more

Safety of Urate-Lowering Therapies

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Safety of Urate-Lowering Therapies

Gout is a metabolic disorder of purine metabolism and uric acid elimination. Over time, acute gout can develop into a chronic, disabling arthropathy, often associated with multiple comorbidities. Gout patients…

read more

Refining Drug Safety in Rheumatology

Oct 1, 2017 by in RHEUMATOLOGY Comments Off on Refining Drug Safety in Rheumatology

John J. Cush, MD, Guest Editor Kathryn H. Dao, MD, Guest Editor An exciting era of rheumatology is upon us. Advances in pathobiology have produced novel advances in the treatment…

read more
Get Clinical Tree app for offline access